## **AMENDMENTS**

## **Amendments to the Specification**

Please replace lines 1-10 of page 7 with the following:

FIG. 1A and 1B: An *in vivo* solubility assay based on structural complementation. (FIG. 1A) A schematic depicting the complementation solubility assay. P (squares) represents the target protein, and  $\alpha$  (triangles) and  $\omega$  (trapezoids) represent each of the complementing fragments of the tetrameric  $\beta$ -galactosidase. Brackets indicate the concentration dependence of the assay regarding the availability of soluble (folded) target/ $\alpha$  fusion.  $K_d$  is indicated solely to highlight the concentration-dependent equilibrium association/dissociation reaction. (FIG. 1B) A schematic representation of the target protein/ $\alpha$ -fragment C-terminal fusion expression construct ( $\alpha$ -fragment, residues 7-58 from full length  $\beta$ -galactosidase). "HA" indicates the position of the inserted influenza hemagglutinin (HA) immuno-tag (residue sequence YPYDVPDYA (SEQ ID NO:1)) present in some of the constructs examined.

Please replace lines 1-7 of page 65 with the following:

G32D/I33P -

5'-GATGCTCAACGGTGACTTTAGGATCGGTATCTTCTCGAATTTC-3' (SEQ ID NO:2)

G32D -

5'-CAACGGTGACTTTAATATCGGTATCTTTCTCG-3' (SEQ ID NO:3)

133P -

5'-GGTGACTTTAGGTCCGGTATCTTTCTCG-3' (SEQ ID NO:4)